X

Drug Profile

KNP 101

Alternative Names: IL-12-Anti-Target A; KNP-101

Latest Information Update: 29 Sep 2020

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kanaph Therapeutics
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 12 replacements; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

28 Sep 2020 Preclinical trials in Solid tumours in South Korea (Parenteral) (Kanaph Therapeutics pipeline, September 2020)
22 Oct 2019 Kanaph Therapeutics in-licenses IP related to the conceptual source technology for TMEkine™ from universities in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com